MedTrace Logo

A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer

NCT03193528 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2026-02-04

No results posted yet for this study

Summary

To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with gross hematuria.

Conditions

Sponsors & Collaborators

  • Fred Hutchinson Cancer Center

    collaborator OTHER

  • University of Texas

    collaborator OTHER

  • Nara Medical University

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • Nonagen Bioscience Corporation

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Rochester

    collaborator OTHER

  • Nara Prefecture Seiwa Medical Center

    collaborator UNKNOWN

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Charles Rosser, MD · Nonagen Bioscience Corporation

  • Hideki Furuya, MD · Cedars-Sinai Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-30
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193528 on ClinicalTrials.gov